ImmTACs: Bi-specific TCR-anti-CD3 fusions for potent redirected killing of cancer cells

Tue2  Sep04:00pm(30 mins)
Charter 3


ImmTACs are soluble TCR-based bi-specific reagents suitable for the treatment of several tumour types. These reagents combine picomolar-affinity antigen recognition, with effective immune-activation via an anti-CD3 antibody fragment, to drive potent T cell redirection and cancer cell killing. Unlike monoclonal antibodies, TCRs target MHC-bound peptide antigens derived from endogenously processed proteins, providing a large pool of intracellular antigens from which to select appropriate target molecules. This presentation will focus on pre-clinical data generated for our current lead ImmTAC candidate, IMCgp100 currently in a phase IIa clinical trial for the treatment of malignant melanoma.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021